Shares of Fresenius SE & Co KGaA (FRA:FRE) have been given an average rating of “Buy” by the twenty-one brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is €70.64 ($82.14).

A number of brokerages recently issued reports on FRE. Deutsche Bank set a €85.00 ($98.84) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Friday, October 5th. Warburg Research set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Thursday, October 4th. Independent Research set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Tuesday, October 2nd. Commerzbank set a €83.00 ($96.51) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Tuesday, October 2nd. Finally, Kepler Capital Markets set a €82.00 ($95.35) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Tuesday, October 2nd.

Shares of FRE stock opened at €47.38 ($55.09) on Friday. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Recommended Story: Dividend Aristocrat Index

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.